The Pfizer logo is seen outside the company’s headquarters on August 8, 2025 in New York City. (Photo by ANGELA WEISS / AFP) (Photo by ANGELA WEISS/AFP via Getty Images)
AFP via Getty Images
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.
The stock remains 3.8% lower than its closing price in 2024, sharply contrasting with the 12.7% year-to-date return posted by the S&P 500.
Despite recent positive news—including strong Phase 3 trial results for a breast cancer treatment and a new acquisition (Metsera) in the weight management sector—these developments have failed to reassure investors. The market’s negative outlook is primarily driven by serious revenue challenges, specifically the looming impact of patent expiries on key blockbuster drugs like Eliquis and Ibrance.
PFE offers biopharmaceutical products, which encompass medicines, vaccines, and biosimilars targeting cardiovascular, metabolic, women’s health, as well as chronic immune and inflammatory conditions. Is this decline a warning sign or an opportunity for recovery? Explore further with Buy or Sell PFE.
Separately, see – S&P 500 Poised For A 40% Crash?
PFE stock has declined significantly of late, and we currently find it appealing. While this may seem like a chance, there is considerable risk in depending solely on one stock. Conversely, a diverse investment strategy like the one we adopt with Trefis High Quality Portfolio offers substantial value. We extend our focus beyond just equities. Would a portfolio comprising 10% commodities, 10% gold, and 2% cryptocurrency, in addition to equities and bonds, be likely to yield higher returns over the next 1-3 years while providing better protection if markets plummet by 20%? We have analyzed the figures.
MORE FOR YOU
Comparing PFE Stock Returns With The S&P 500
The table below outlines the returns for PFE stock compared to the S&P 500 index over several different durations, including the ongoing streak:
Comparing PFE Stock Returns With The S&P 500
Trefis
What is the significance? Prolonged weakness can signify more than mere noise. It often indicates a shift in sentiment or deeper issues. A multi-day losing pattern might forewarn of additional declines or could represent an opportunity to buy, provided that the fundamentals remain sound.
Gains and Losses Streaks: S&P 500 Constituents
Currently, there are 50 S&P constituents with consecutive gains spanning 3 days or longer, and 36 constituents exhibit losses over the same period.
Gains and Losses Streaks: S&P 500 Constituents
Trefis
Key Financials for Pfizer (PFE)
Trefis
The current losing streak of PFE stock does not instill much confidence in investors. Conversely, Trefis High Quality (HQ) Portfolio, which consists of 30 stocks, has consistently outperformed its benchmark, encompassing all three indices – the S&P 500, S&P mid-cap, and Russell 2000. What is the reason? Collectively, HQ Portfolio stocks have yielded superior returns with reduced risk compared to the benchmark index, offering a smoother ride, as demonstrated in HQ Portfolio performance metrics.